Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
C. Reisner, E. St. Rose, S. Strom, T. Fischer, M. Golden, M. Thomas, C. Orevillo (Morristown, Raleigh, United States Of America; Toowong, Australia)
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Session: Bronchodilators in asthma and COPD
Session type: Thematic Poster Session
Number: 879
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Reisner, E. St. Rose, S. Strom, T. Fischer, M. Golden, M. Thomas, C. Orevillo (Morristown, Raleigh, United States Of America; Toowong, Australia). Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Eur Respir J 2011; 38: Suppl. 55, 879
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A randomised, 4-way crossover study to examine the lung pharmacodynamic effects of single inhaled doses of tiotropium (18 μg), salmeterol (50 μg), tiotropium (18 μg) and salmeterol (50 μg) and placebo using whole body plethysmography in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Randomized clinical trial (RCT) comparing formoterol vs. salbutamol plus ipratropium bromide in the treatment of acute asthma exacerbation (AE) at emergency room (ER) Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
A double-blind, single dose, four period, crossover study to demonstrate the equivalence between the two HFA formulations of formoterol fumarate; using serial spirometry measurements for 12 hrs Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Source: Eur Respir J 2002; 20: 1138-1146 Year: 2002
The TRIFLOW study; A randomised, cross-over study evaluating the effects of inhaled beclometasone/formoterol/glycopyrronium (BDP/F/G) on hyperinflation in COPD Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Randomised, double-blind, double-dummy, parallel-group comparison of the effect of fluticasone propionate (FP) 100 μg bd and budesonide (BUD) 200 μg bd on childhood growth: protocol and baseline characteristics Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015